Notes d’épisode
Episode 154 — 30 October 2026
Examining HCA's profit warning as an access erosion signal, subcutaneous Leqembi's HEOR implications, FTC-CVS insulin settlement impact on PBMs, and ICER's early-phase scientific advice expansion.
Hosted by Marcus and Sara.
Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
Full transcript and sources at outcomes-analytica.no/podcast

